Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials
Y Tanaka, R Tummala - Modern Rheumatology, 2021 - academic.oup.com
Chronic activation of the type I interferon (IFN) pathway plays a critical role in systemic lupus
erythematosus (SLE) pathogenesis. Anifrolumab is a human monoclonal antibody to the …
erythematosus (SLE) pathogenesis. Anifrolumab is a human monoclonal antibody to the …
Interferon inhibition for lupus with anifrolumab: critical appraisal of the evidence leading to FDA approval
MF Loncharich, CW Anderson - 2022 - Wiley Online Library
Journal Club Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al.
Anifrolumab, an anti‐interferon‐α receptor monoclonal antibody, in moderate‐to‐severe …
Anifrolumab, an anti‐interferon‐α receptor monoclonal antibody, in moderate‐to‐severe …
[HTML][HTML] Trial of anifrolumab in active systemic lupus erythematosus
Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
Long‐term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open‐label extension study
WW Chatham, R Furie, A Saxena… - Arthritis & …, 2021 - Wiley Online Library
Objective To investigate long‐term safety and tolerability of anifrolumab, a human
monoclonal antibody to the type I interferon (IFN) receptor subunit 1, in patients with …
monoclonal antibody to the type I interferon (IFN) receptor subunit 1, in patients with …
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 …
Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease
characterised by multisystem involvement. We aimed to evaluate the efficacy of anifrolumab …
characterised by multisystem involvement. We aimed to evaluate the efficacy of anifrolumab …
[PDF][PDF] Anifrolumab, an anti–interferon‐α receptor monoclonal antibody, in moderate‐to‐severe systemic lupus erythematosus
R Furie, M Khamashta, JT Merrill… - Arthritis & …, 2017 - Wiley Online Library
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
A randomized, placebo‐controlled phase III extension trial of the long‐term safety and tolerability of anifrolumab in active systemic lupus erythematosus
KC Kalunian, R Furie, EF Morand… - Arthritis & …, 2023 - Wiley Online Library
Objective To explore long‐term safety and tolerability of anifrolumab 300 mg compared with
placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of …
placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of …
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III …
Objectives To characterise the efficacy and safety of anifrolumab in patients with systemic
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …
Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
R Felten, F Scher, F Sagez, F Chasset… - Drug design …, 2019 - Taylor & Francis
Previous reports have described the appearance of systemic lupus erythematosus (SLE)
cases following interferon-α (IFN-α) therapy, IFN-regulated gene expression is significantly …
cases following interferon-α (IFN-α) therapy, IFN-regulated gene expression is significantly …
相关搜索
- tulip 1 lupus erythematosus
- efficacy of anifrolumab lupus erythematosus
- monoclonal antibody lupus erythematosus
- tulip 1 efficacy of anifrolumab
- interferon α lupus erythematosus
- tulip 1 organ domains
- rash and arthritis lupus erythematosus
- organ domains lupus erythematosus
- anifrolumab in adults lupus erythematosus
- tulip 2 lupus erythematosus
- tolerability of anifrolumab lupus erythematosus
- tulip 2 efficacy of anifrolumab